Tenosynovial Giant Cell Tumors Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – AmMax Bio, Deciphera Pharma, Daiichi Sankyo

Posted on
by

Tenosynovial Giant Cell Tumors Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - AmMax Bio, Deciphera Pharma, Daiichi Sankyo
DelveInsight’s “Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors.

DelveInsight’s “Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tenosynovial Giant Cell Tumors Market Forecast

 

Some of the key facts of the Tenosynovial Giant Cell Tumors Market Report:

  • The Tenosynovial Giant Cell Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the National Organization for Rare Disorders (2022), tenosynovial giant cell tumors mainly affect individuals between 25-50 years of age, with a median age of diagnosis of 40
  • According to the National Institute For Health and Care Excellence (2022), TGCT mainly affects adults between 20 and 50 years. The annual incidence has been estimated at between 11 and 43 in 1,000,0001
  • Diffuse forms are mainly intra-articular, in the knee (75% of cases), hip, ankle or shoulder, although all synovial joints may be involved: temporomandibular, spinal inter-apophyseal joints, etc.
  • Key Tenosynovial Giant Cell Tumors Companies: AmMax Bio, Deciphera Pharma, Daiichi Sankyo, Inc., Abbisko Therapeutics, Plexxikon, Deciphera Pharma, SynOx Therapeutics, Abbisko Therapeutics, Novartis, Dragonboat Biopharma, and others
  • Key Tenosynovial Giant Cell Tumors Therapies: AMB-05X, Vimseltinib, Pexidartinib, Pimicotinib(ABSK021), PLX73086, vimseltinib, Emactuzumab, ABSK021, MCS110, BC006, and others
  • The Tenosynovial Giant Cell Tumors epidemiology based on gender analyzed that there are more cases of Localized Tenosynovial Giant Cell Tumors in females than males
  • The Tenosynovial Giant Cell Tumors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tenosynovial Giant Cell Tumors pipeline products will significantly revolutionize the Tenosynovial Giant Cell Tumors market dynamics.

 

Tenosynovial Giant Cell Tumors Overview

According to the National Organization for Rare Disorders (2022), tenosynovial giant cell tumors (TGCTs) are a group of rare, benign tumors that involve the synovium, bursae and tendon sheath. Synovium is the thin layer of tissue or membrane that covers the inner surface of the joint spaces and the bursae and tendon sheaths. The bursae are small fluid-filled sacs that cushion bones, tendons and muscles around the joints. A tendon sheath is a layer membrane that covers a tendon. Tendons are fibrous tissue that connects muscle to bone.

 

Get a Free sample for the Tenosynovial Giant Cell Tumors Market Report 

https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market

 

Tenosynovial Giant Cell Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Tenosynovial Giant Cell Tumors Epidemiology Segmentation:

The Tenosynovial Giant Cell Tumors market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Tenosynovial Giant Cell Tumors
  • Prevalent Cases of Tenosynovial Giant Cell Tumors by severity
  • Gender-specific Prevalence of Tenosynovial Giant Cell Tumors
  • Diagnosed Cases of Episodic and Chronic Tenosynovial Giant Cell Tumors

 

Download the report to understand which factors are driving Tenosynovial Giant Cell Tumors epidemiology trends @ Tenosynovial Giant Cell Tumors Epidemiology Forecast

 

Tenosynovial Giant Cell Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to get launched during the study period. The analysis covers Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tenosynovial Giant Cell Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Tenosynovial Giant Cell Tumors Therapies and Key Companies

  • AMB-05X: AmMax Bio
  • Vimseltinib: Deciphera Pharmaceutical
  • Pexidartinib: Daiichi Sankyo, Inc.
  • Pimicotinib(ABSK021): Abbisko Therapeutics
  • PLX73086: Plexxikon
  • vimseltinib: Deciphera Pharma
  • Emactuzumab: SynOx Therapeutics
  • ABSK021: Abbisko Therapeutics
  • MCS110: Novartis
  • BC006: Dragonboat Biopharma

 

Discover more about therapies set to grab major Tenosynovial Giant Cell Tumors market share @ Tenosynovial Giant Cell Tumors Treatment Market

 

Scope of the Tenosynovial Giant Cell Tumors Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Tenosynovial Giant Cell Tumors Companies: AmMax Bio, Deciphera Pharma, Daiichi Sankyo, Inc., Abbisko Therapeutics, Plexxikon, Deciphera Pharma, SynOx Therapeutics, Abbisko Therapeutics, Novartis, Dragonboat Biopharma, and others
  • Key Tenosynovial Giant Cell Tumors Therapies: AMB-05X, Vimseltinib, Pexidartinib, Pimicotinib(ABSK021), PLX73086, vimseltinib, Emactuzumab, ABSK021, MCS110, BC006, and others
  • Tenosynovial Giant Cell Tumors Therapeutic Assessment: Tenosynovial Giant Cell Tumors current marketed and Tenosynovial Giant Cell Tumors emerging therapies
  • Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors market drivers and Tenosynovial Giant Cell Tumors market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Tenosynovial Giant Cell Tumors Unmet Needs, KOL’s views, Analyst’s views, Tenosynovial Giant Cell Tumors Market Access and Reimbursement 

 

To know more about Tenosynovial Giant Cell Tumors companies working in the treatment market, visit @ Tenosynovial Giant Cell Tumors Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Tenosynovial Giant Cell Tumors Market Report Introduction

2. Executive Summary for Tenosynovial Giant Cell Tumors

3. SWOT analysis of Tenosynovial Giant Cell Tumors

4. Tenosynovial Giant Cell Tumors Patient Share (%) Overview at a Glance

5. Tenosynovial Giant Cell Tumors Market Overview at a Glance

6. Tenosynovial Giant Cell Tumors Disease Background and Overview

7. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Tenosynovial Giant Cell Tumors 

9. Tenosynovial Giant Cell Tumors Current Treatment and Medical Practices

10. Tenosynovial Giant Cell Tumors Unmet Needs

11. Tenosynovial Giant Cell Tumors Emerging Therapies

12. Tenosynovial Giant Cell Tumors Market Outlook

13. Country-Wise Tenosynovial Giant Cell Tumors Market Analysis (2019–2032)

14. Tenosynovial Giant Cell Tumors Market Access and Reimbursement of Therapies

15. Tenosynovial Giant Cell Tumors Market Drivers

16. Tenosynovial Giant Cell Tumors Market Barriers

17.  Tenosynovial Giant Cell Tumors Appendix

18. Tenosynovial Giant Cell Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services